|
|
|
|
|
|
|
|
|
Key Consultants :
Dr Graham Jackson, BSc (Hons), PhD.
Michael Stone MA Professor David Anstee PhD, FRCPath, FMedSci
He obtained BSc and PhD from the Department of Biochemistry in the University of Bristol. His research focusses on the characterisation of membrane proteins, particularly those of the human red blood cell and he has published numerous research papers in this field. He has been involved in the production and characterisation of monoclonal antibodies (mouse, rat and human) for use in research and as diagnostic and therapeutic products for the past 25 years. Since 1997 he has collaborated with Professor Collinge regarding the production of monoclonal antibodies against prion protein.
Dr David Whitehouse, BSc, Phd.
Dr Rosey Mushens, BSc, PhD Dr Jonathan Wadsworth, BSc, PhD.
Dr William Richards BSc, PhD.
Dr Andrew Wright BSc (Hons), D.Phil.
|
 |
|
Our
Team
Michael
has more than 30 years experience working in the pharmaceuticals and
biotechnology industries and currently leads the transactional life sciences
practice of law firm Covington & Burling in London. Before joining the firm,
Michael worked in a variety of legal and commercial roles within Glaxo Holdings
plc and its successor organizations ("Glaxo"). After leaving Glaxo, he acted as
an independent consultant to small and medium sized companies in the life
sciences sector, providing advice and support on licensing arrangements and
research collaborations.
Professor
David Anstee is the Director of the Bristol Institute for Transfusion Sciences,
an affiliated Institute of the University of Bristol which includes the
International Blood Group Reference Laboratory (IBGRL), a World Health
Organisation Collaborating Centre. He is also the Research co-ordinator for the
National Blood Service in England. 
David has more than 20 years research experience,
mostly with the MRC in The Galton Laboratory, UCL. After graduating from Sussex
University (Biology) and a PhD in genetics from Nottingham University he was
awarded a post-doctoral fellowship at the Institute of Zoology London. In 1983
he was appointed to the MRC Human Biochemical Genetics Unit in UCL. His research
covered human genetic variation at the molecular and protein levels, protein
phylogenies, genome instability and the development of rapid low-cost tests for
specific protein variants using monoclonal antibodies. David gained commercial
experience over two years, including patenting activities and IP portfolio
management as R&D Manager at ZetaGen. He has collaborated with biotechnology
companies in the development of high sensitivity gene product analysis and is an
active biotechnology / proteomics consultant to industry and academia.
Rosey
is the monoclonal antibody development section manager at the International
Blood Group Reference Laboratory in Bristol and has over 18 years experience in
the production and development of monoclonal antibodies. She obtained her BSc
from Coventry University and her PhD from the University of the West of England.
Since April 1991, she has been marketing a range of monoclonal antibodies to red
cell, white cell and platelet antigens for immunohaematologists for IBGRL
Research Products. She has been working on the production of antibodies against
prions (the ICSM cell lines) since June 1998. Rosey is also involved in the
development of antibody engineered cell lines and the production of monoclonal
antibodies for various therapeutic trials which form part of the remit of the
Bristol Institute for Transfusion Sciences. She also manufactures and supplies
developing countries designated by the World Health Organisation with monoclonal
antibodies suitable for use as blood grouping reagents. 
Jonathan
Wadsworth graduated with a BSc in Biochemistry from Imperial College, London in
1986. In 1990 he was awarded a PhD in Molecular Neurobiology from Imperial
College, London for work with Professor Oliver Dolly investigating the neuro-paralytic
activities of Clostridial neurotoxins. In 1991 he joined the Muscular Dystrophy
Group laboratories of Professor Victor Dubowitz at Imperial College School of
Medicine, London. In 1993 he was appointed as a Principal Research Officer and
collaborated with Dr Peter Strong investigating the structure and pharmacology
of neuronal calcium-activated potassium channels. In 1997 he joined the MRC
Prion Unit to work with Professor John Collinge. He is currently an MRC
programme leader track scientist within the MRC Prion Unit and an honorary
lecturer within the Department of Neurodegenerative Disease, University College,
London.
William holds a BSc in Biological Sciences (Leicester
University), PhD in Molecular Genetics (Leicester University and Geneva
Institute of Molecular Biology), Postgraduate Certificate in Intellectual
Property Law (London University) and was elected as an Associate Member of the
Chartered Institute of Patent Agents in 2000. He did his post-doctoral research
fellowship at the Institute of Cancer Research, London and is currently European
Patent Attorney with K R Bryer & Co. Williams area of speciality is in
biotechnology including molecular biology, genomics, gene sequences, array
technology, structural biology, bioinformatics, assays, diagnostics, medical
devices, stem cells, vaccines, drug delivery, therapeutics and food technology.
Andrew
read molecular biology and biochemistry at Durham University, subsequently
obtained a D.Phil from Oxford University and has been working as a patent
attorney, specialising in biotechnology, since 1998. He is a registered UK
Patent Agent, a European Patent Attorney and an associate of the Chartered
Institute of Patent Agents (CIPA). 
|
|
|
|
|
Copyright ©2008 D-Gen Ltd. |
|
